IMRX Stock Analysis: Buy, Sell, or Hold?
IMRX - Immuneering Corporation Class A Common Stock
$4.63
-0.24 (-4.93%)
▼
WAIT
LOW Confidence
Last Updated: January 30, 2026
Earnings: Mar 19, 2026
Get Alerted When IMRX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
1 traders called IMRX this week
100% bullish • 0 bearish
100% bullish • 0 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: IMRX is down 13.6% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: IMRX is down 13.6% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: IMRX is currently trading at $4.63, which is considered slightly low relative to its 30-day fair value range of $4.53 to $6.64.
Technical Outlook: Technically, IMRX is in a strong uptrend. Immediate support is located at $4.35, while resistance sits at $5.55. Short-term momentum is weak, with the stock down 4.9% recently.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $16.83 (+263.6%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, IMRX is in a strong uptrend. Immediate support is located at $4.35, while resistance sits at $5.55. Short-term momentum is weak, with the stock down 4.9% recently.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $16.83 (+263.6%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Fair Price Range
$4.53 -
$6.64
Company Quality Score
52/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
77.4%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (45/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-4.9%)
- BULLISH: Trading 263.6% below Wall St target ($16.83)
- WARNING: Recommendation downgraded due to -13.6% 5-day decline - wait for stabilization
Fair Price Analysis
30-Day Fair Range
$4.53 -
$6.64
Current vs Fair Value
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$4.35
Resistance Level
$5.55
Current Trend
Strong Uptrend
Fundamental Context
Forward P/E (Next Year Est.)
-3.17
Wall Street Target
$16.83
(+263.6%)
Revenue Growth (YoY)
-99.8%
Last updated: February 01, 2026 7:16 PM ET
Data refreshes hourly during market hours. Next update: 8:16 PM
Data refreshes hourly during market hours. Next update: 8:16 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is IMRX showing a specific setup today?
Insider Activity (6 Months)
4
Buys
0
Sells
+
Net
INSIDERS BUYING
Recent Transactions
Peter Feinberg
BUY
7500 shares
2025-10-03
Leah R Neufeld
BUY
800 shares
2025-10-01
Peter Feinberg
BUY
7500 shares
2025-09-30
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$24 | 60 HOLD |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1036 | 58 HOLD |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$85 | 57 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$33 | 60 HOLD |
|
KYMR
Kymera Therapeutics Inc |
STRONG BUY
20 analysts |
$117 | 59 HOLD |
